Clinical Trials Logo

Walking Capacity clinical trials

View clinical trials related to Walking Capacity.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05860244 Not yet recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients

WALKALS
Start date: September 2024
Phase: Phase 2
Study type: Interventional

Preclinical and clinical data strongly suggest that administration of salbutamol in ALS patients may improve walking capacity related to motor fatigue by enhancing neuromuscular transmission. Salbutamol may exert a neuroprotective effect and slow down the progression of clinical signs and symptoms. The main objective of the study is to test the efficacy of salbutamol on walking capacity in ALS patients and the secondary objective is to measure the target engagement of salbutamol on the neuromuscular junction (NMJ) at EMG (decrement of repetitive nerve stimulation in three nerves/muscle couples), as well as safety and tolerability. The exploratory objectives are to study the effect of salbutamol on fatigue scales, muscle strength, respiratory function, motor unit count, muscle and spinal MRI parameters and blood biomarkers